Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Unknown 3Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 226OTHER 199NIH 12NETWORK 11OTHER_GOV 5UNKNOWN 4

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 4Tumor-Agnostic 1

Conditions

Breast Neoplasms 3Neoplasms 1Estrogen Receptor Positive Breast Cancer 1

Interventions

Cisplatin 49Capecitabine 42Radiotherapy 33Oxaliplatin 33Gemcitabine 33apatinib 32Cyclophosphamide 32Drug Therapy 31Paclitaxel 30Carboplatin 29tislelizumab 27Irinotecan 27Fluorouracil 26Docetaxel 26Bevacizumab 23Surgical Procedures, Operative 20Nivolumab 19pembrolizumab 18fludarabine 18Metformin 16Exercise 16Radiation 15camrelizumab 14S 1 (combination) 14Control Groups 14Blood Specimen Collection 14Pemetrexed 13Standard of Care 12anlotinib 11Neoadjuvant Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER_GOV × Fulvestrant × Clear all
NCT01992952 2025-11-26

FAKTION

Velindre NHS Trust

Phase 1/2 Active not recruiting
149 enrolled
Breast

Estrogen Receptor Positive Breast Cancer

NCT05176080 2024-12-17

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Henan Cancer Hospital

Phase 1/2 Terminated
46 enrolled
Breast

Breast Neoplasms

NCT05328440 2023-09-25

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

Henan Cancer Hospital

Phase 2 Unknown
120 enrolled
Breast

Breast Neoplasms

NCT03024580 2019-08-15

MEGA

Instituto Nacional de Cancer, Brazil

Phase 2 Unknown
20 enrolled
Breast

Breast Neoplasms

NCT02530411 2015-08-21

FURVA

Velindre NHS Trust

Phase 2 Unknown
160 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡